Single-Center Randomized Trial Comparing Feeding Jejunostomy with Nasojejunal Tube Placement in Patients Undergoing Transhiatal Esophagectomy Post-Neoadjuvant Therapy for Esophageal Cancer
Journal of Gastrointestinal Cancer · 2024
DOI: 10.1007/s12029-024-01080-0 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gastrointestinal Cancer, 2024. Verfasst von Lokesh Agarwal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Gastroenterology, All India Institute of Medical Sciences (AIIMS), Jodhpur, India. Hauptthemen laut MEDLINE: Esophagectomy, Esophageal Neoplasms, Enteral Nutrition, Jejunostomy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Enteral nutrition is the preferred mode of nutrition following esophagectomy. However, the preferred mode of enteral nutrition (feeding jejunostomy (FJ) vs. nasojejunal (NJ) tube) remains contentious. In this randomized controlled trial (RCT), we compared FJ with NJ tube feeding in terms of safety, feasibility, efficacy, and quality-of-life (QOL) parameters in Indian patients undergoing trans-hiatal esophagectomy (THE) for carcinoma esophagus. MATERIALS AND METHODS: This single-center, two-armed (FJ and NJ tube), non-inferiority RCT was conducted from March 2020 to January 2024. Forty-eight patients underwent THE with posterior-mediastinal-gastric pull-up and were randomized to NJ and FJ arms (24 in each group). The postoperative complications, catheter efficacy, and QOL parameters were compared between the two groups till the 6-week follow-up. RESULTS: In this RCT, we found no significant difference in the occurrence of catheter-related complications, postoperative complication rate, catheter efficacy, and visual analog pain scores between patients with NJ tube and FJ, following THE for esophageal cancer. There was a significantly better self-reported physical domain QOL score noted in the NJ group, both at the time of discharge (44.7 ± 6.2 vs 39.8 + 5.6; p value, 0.005) and at the 6-week follow-up (55.4 ± 5.2 vs 48.6 ± 4.5; p value, < 0.001). CONCLUSION: Based on the findings of our RCT, we conclude that both enteral access methods (NJ vs. FJ) exhibit comparable incidences of catheter-related complications. The use of NJ tube is a viable alternative to a surgical FJ, has the benefit of early removal, and saves the distress associated with a tube per abdomen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Gastroenterology, All India Institute of Medical Sciences (AIIMS), Jodhpur, India.
- Department of Gastrointestinal Surgery and Liver Transplant, All India Institute of Medical Sciences (AIIMS), New Delhi, India. nagranjan@gmail.com.
- Department of Gastrointestinal Surgery and Liver Transplant, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
- Department of Radiodiagnosis, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Zitieren
APA
Agarwal, L., Dash, N. R., Pal, S., Madhusudhan, K. S., & Mani, V. (2024). Single-Center Randomized Trial Comparing Feeding Jejunostomy with Nasojejunal Tube Placement in Patients Undergoing Transhiatal Esophagectomy Post-Neoadjuvant Therapy for Esophageal Cancer. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-024-01080-0
Vancouver
Agarwal L, Dash NR, Pal S, Madhusudhan KS, Mani V. Single-Center Randomized Trial Comparing Feeding Jejunostomy with Nasojejunal Tube Placement in Patients Undergoing Transhiatal Esophagectomy Post-Neoadjuvant Therapy for Esophageal Cancer. Journal of Gastrointestinal Cancer. 2024. doi:10.1007/s12029-024-01080-0
BibTeX
@article{Agarwal2024,
author = {Agarwal, Lokesh and Dash, Nihar Ranjan and Pal, Sujoy and Madhusudhan, Kumble Seetharama and Mani, Vignesh},
title = {Single-Center Randomized Trial Comparing Feeding Jejunostomy with Nasojejunal Tube Placement in Patients Undergoing Transhiatal Esophagectomy Post-Neoadjuvant Therapy for Esophageal Cancer},
journal = {Journal of Gastrointestinal Cancer},
year = {2024},
doi = {10.1007/s12029-024-01080-0}
}
EUVIMED